Item 7.01 Regulation FD

On September 20, 2021, Lexaria Bioscience Corp. ("Lexaria") was advised that an investor report (the "Report") on Lexaria had been published by Zacks Investment Research, Inc. ("Zacks") and disseminated via institutional investor platforms, retail investor platforms, social media and directly to their subscribers.

Lexaria has paid Zacks US$39,000 to provide analyst coverage for a year which includes an on-site visit, the preparation of the Report and four quarterly updates to the Report. The Report contains certain future projections for Lexaria's revenues for the 2021, 2022 and 2023 fiscal years as well as valuations. A full copy of the Report is attached hereto as Exhibit 99.1.

© Edgar Online, source Glimpses